MedTrace Logo

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules

NCT07507838 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-14

No results posted yet for this study

Summary

This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics （PK） of multiple doses of VV913 in Chinese healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

VV913 4mg group

6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

DRUG

VV913 8mg group

6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

DRUG

VV913 15mg group

6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-13
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07507838 on ClinicalTrials.gov